In the group with age at breast cancer diagnosis of ≥60 years, the highest 5-year cumulative probability of osteoporosis was observed in women who received AIs following a combination of chemotherapy and anti-HER2 therapy at 45.1%, followed by those who received AIs after chemotherapy at 42.4%. The gene discussed is ERBB2; the disease is osteoporosis.